HealthTree Logo
search more_vert
App Logo
person Sign In / Create Account
Clinical Trial: Dendritic Cell Vaccine with Stem Cell Transplant Now Open
Posted: Aug 02, 2016
Clinical Trial: Dendritic Cell Vaccine with Stem Cell Transplant Now Open image

Stem cell transplant is a core myeloma therapy and is effective at eliminating the bulk of myeloma cells but residual cells can remain, causing eventual relapse. A new clinical trial is now open that uses an immunotherapy vaccine to go after these residual cells. This is a Phase II, multi-center study (16 centers) that is comparing autologous stem cell transplant and lenalidomide maintenance vs. autologous stem cell transplant, lenalidomide maintenance and the dendritic cell myeloma vaccine. To learn more about this approach, listen to Dr. David Avigan explain this clinical trial on Myeloma Crowd Radio or watch Dr. Avigan on Myeloma Crowd TV (at 16:46). Click here to find the open clinical trial: Dendritic Cell Vaccine with SCT Clinical Trial  

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of HealthTree Foundation (formerly Myeloma Crowd). 

Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Janssen Oncology
Adaptive Biotechnologies
Amgen Oncology
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube